



# Targeting PI3K-gamma in myeloid driven tumour immune suppression: a systematic review and meta-analysis of the preclinical literature

Haonan Xu<sup>1</sup> · Shannon Nicole Russell<sup>2</sup> · Katherine Steiner<sup>3</sup> · Eric O'Neill<sup>1</sup> · Keaton Ian Jones<sup>2</sup>

Received: 7 December 2023 / Accepted: 11 July 2024 / Published online: 6 August 2024  
© The Author(s) 2024

## Abstract

The intricate interplay between immune and stromal cells within the tumour microenvironment (TME) significantly influences tumour progression. Myeloid cells, including tumour-associated macrophages (TAMs), neutrophils (TANs), and myeloid-derived suppressor cells (MDSCs), contribute to immune suppression in the TME (Nakamura and Smyth in *Cell Mol Immunol* 17(1):1–12 (2020). <https://doi.org/10.1038/s41423-019-0306-1>; DeNardo and Ruffell in *Nat Rev Immunol* 19(6):369–382 (2019). <https://doi.org/10.1038/s41577-019-0127-6>). This poses a significant challenge for novel immunotherapeutics that rely on host immunity to exert their effect. This systematic review explores the preclinical evidence surrounding the inhibition of phosphoinositide 3-kinase gamma (PI3K $\gamma$ ) as a strategy to reverse myeloid-driven immune suppression in solid tumours. EMBASE, MEDLINE, and PubMed databases were searched on 6 October 2022 using keyword and subject heading terms to capture relevant studies. The studies, focusing on PI3K $\gamma$  inhibition in animal models, were subjected to predefined inclusion and exclusion criteria. Extracted data included tumour growth kinetics, survival endpoints, and immunological responses which were meta-analysed. PRISMA and MOOSE guidelines were followed. A total of 36 studies covering 73 animal models were included in the review and meta-analysis. Tumour models covered breast, colorectal, lung, skin, pancreas, brain, liver, prostate, head and neck, soft tissue, gastric, and oral cancer. The predominant PI3K $\gamma$  inhibitors were IPI-549 and TG100-115, demonstrating favourable specificity for the gamma isoform. Combination therapies, often involving chemotherapy, radiotherapy, immune checkpoint inhibitors, biological agents, or vaccines, were explored in 81% of studies. Analysis of tumour growth kinetics revealed a statistically significant though heterogeneous response to PI3K $\gamma$  monotherapy, whereas the tumour growth in combination treated groups were more consistently reduced. Survival analysis showed a pronounced increase in median overall survival with combination therapy. This systematic review provides a comprehensive analysis of preclinical studies investigating PI3K $\gamma$  inhibition in myeloid-driven tumour immune suppression. The identified studies underscore the potential of PI3K $\gamma$  inhibition in reshaping the TME by modulating myeloid cell functions. The combination of PI3K $\gamma$  inhibition with other therapeutic modalities demonstrated enhanced antitumour effects, suggesting a synergistic approach to overcome immune suppression. These findings support the potential of PI3K $\gamma$ -targeted therapies, particularly in combination regimens, as a promising avenue for future clinical exploration in diverse solid tumour types.

---


✉ Keaton Ian Jones  
keaton.jones@nds.ox.ac.uk

<sup>1</sup> Department of Oncology, University of Oxford, Oxford, UK

<sup>2</sup> Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK

<sup>3</sup> Bodleian Health Care Libraries, University of Oxford, Oxford, UK

## Graphical abstract



**Keywords** PI3K-gamma · Macrophage · Repolarisation · Tumour · Meta-analysis

## Introduction

As our understanding of the complex tumour microenvironment (TME) has evolved, novel strategies that selectively target individual intertumoural components have been widely reported [1, 2]. The TME is comprised of immune and stromal cells, extracellular matrix, vascular networks, and cellular mediators alongside cancer cells. Host immune and stromal cells can be tissue resident or recruited from the systemic circulation and include macrophages, neutrophils, myeloid-derived suppressor cells (MDSCs), T lymphocytes, B lymphocytes, Natural Killer cells (NK), innate lymphoid cells (ILCs), and Fibroblasts. Cancer cells interact with these populations and can polarise their phenotypes in favour of tumour progression (i.e. tumour associated macrophage, TAM; tumour associated neutrophil, TAN; and cancer associated fibroblast, CAF) [3–7]. Exploring the mechanisms of resistance to therapeutic strategies has underscored the critical contribution of the TME across a range of solid tumours. Foremost amongst these have been immune checkpoint inhibitors. Despite revolutionising the prognosis in select patient cohorts, checkpoint blockade remains ineffective in many solid tumour types [8]. Both preclinical and clinical studies have demonstrated that myeloid cells (TAMs, TANs, MDSCs) appear to play a critical immune suppressive role within the TME [9]. It is becoming clear that combinational approaches that target multiple components of the TME may be needed to overcome barriers to effective anti-tumour immunity. One of these approaches is the reversal of immune suppression by selectively targeting myeloid cells.

Decades of research have contributed to a comprehensive insight into the role of myeloid cells within the TME across multiple solid tumours. Myeloid populations comprising macrophages, monocytes (e.g. myeloid-derived suppressor cells), and granulocytes (e.g. neutrophils) have

been shown to exert pro-tumourigenic functions. Expanding from the historic M1/M2 paradigm, tumoural macrophage phenotype has now been accepted as a continuum of heterogenous and pleotropic populations that respond to external selection pressure. This functional diversity means that unselective TAM depletion can deprive the TME of macrophages that are integral to promoting anti-tumour activity. Alternative strategies include those that aim to augment specific macrophage functions, such as phagocytosis [10] and angiogenesis [11], and those that reprogram macrophages through metabolic, epigenetic, and signalling pathways [12, 13]. Reprogramming strategies are particularly attractive as they retain the potential benefits of inflammatory macrophages that may be an essential component of the anti-tumour immune cascade. One such approach is inhibition of the Phosphoinositide 3-Kinase gamma pathway.

Phosphoinositide 3-Kinase (PI3K) signalling plays a role in a wide range of biological processes. Class I PI3Ks are divided into class IA (comprising PI3K- $\alpha$ ,  $\beta$ , and  $\delta$ ) and class 1B (consisting of PI3K- $\gamma$ ). Isoforms PI3K- $\alpha$  and PI3K- $\beta$  are expressed in a wide range of cells including epithelial cells, PI3K- $\delta$  is expressed in T lymphocytes, and PI3K- $\gamma$  is uniquely expressed in myeloid cells [14]. Activation of PI3K- $\gamma$  leads to upregulation of signalling processes that are associated with an immune suppressive phenotype [15]. Recent years have seen a large increase in the number of preclinical reports highlighting the role of PI3K- $\gamma$  in tumour progression, as well as the effect of PI3K- $\gamma$  inhibition using novel small molecule inhibitors. This can be attributed to the emergence of several isoform specific drugs that improved selectivity and avoided unwanted off target effects. In addition, there are now PI3K- $\gamma$  inhibitors being tested in early phase clinical trials with promising results [16]. We have systemically reviewed the current preclinical literature reporting on the effect of PI3K- $\gamma$  inhibition in

pre-clinical tumour models. Meta-analysis of tumour growth kinetic data, survival endpoints, as well as immunological responses provided valuable insights into the trends associated with this novel treatment strategy.

## Methods

### Search strategy

This review was conducted with reference to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) and reported using the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA). A qualified medical librarian conducted the literature searches on 6 October 2022. The following databases were searched individually for relevant studies: Medline and Embase (both via Ovid) and PubMed (via National Library of Medicine). As the review was solely concerned with pre-clinical models, it was not deemed necessary to search trial registers. The search strategies included a combination of keyword searches and subject heading searches for synonyms of PI3K $\gamma$  and very broad subject heading and keyword terms for cancer. As there is a lot of inconsistency in how PI3K $\gamma$  is referred to and written (exacerbated by databases transliterating the Greek letter  $\gamma$  in inconsistent ways), many synonyms and a proximity search were necessary to create a sensitive search. Drug names, chemical designations, and commercial trademarked names were included. The full search strategies for each database can be viewed in the “Supplementary material”. A total of 3128 results were retrieved from the searches (1970 after removal of duplicates). No search limits or filters were applied, for example study type, publication date or language. The results were deduplicated using EndNote, Deduklick (via risklick.ch), and Rayyan. Reference lists of key articles were hand-searched.

### Inclusion criteria

#### Population

**Inclusion:** Studies reporting the outcome of preclinical mouse or rat experiments.

**Exclusion:** Clinical trials and studies involving human subjects. Ex vivo studies. In vitro studies.

#### Intervention

**Inclusion:** The use of PI3K $\gamma$  selective inhibitors (can be delta/gamma isoform specific) as mono- or combinational therapy for cancer. All timings, dosages, frequencies, and administration routes.

**Exclusion:** Treatment involving Pan PI3K inhibitors (not described as gamma selective) or genetic depletion of PI3K $\gamma$  (e.g. knockout mice).

### Comparator

**Inclusion criteria:** No treatment group, vehicle-treated group, or treatments that do not target PI3K in the case of combinational therapy.

**Exclusion criteria:** Healthy animals, animals that did not develop tumour where a tumour is expected.

### Outcome

**Inclusion criteria:** Reported survival and/or tumour growth outcomes.

**Exclusion criteria:** No relevant outcomes reported.

### Additional exclusion criteria

Include only publications in English. Exclude conference abstracts, posters, reviews, editorials, and theses.

### Procedure for study selection

Studies were selected through two rounds of screening. In the first round, only the title and abstract were screened. Selected articles then underwent full-text review in the second round of screening. Each round of screening was done by 2 reviewers independently, any discrepancies was resolved through discussion and consultation with the full study team of 4 reviewers.

### Data extraction methods

Data were tabulated by 2 reviewers and any discrepancies were discussed. Disease model, intervention method, dosage, schedule, survival outcome, and any immunological characterisations (by flow cytometry) were extracted for each model. For tumour growth data with fixed volumetric endpoint, time to reach end point was recorded, and vice versa. For median survival, time to reach 50% survival from Kaplan–Meier curves were recorded. GEM tumour models were excluded from survival data due to long incubation periods. Quantitative data were extracted from graphs through digital annotations.

### Data extraction

Extracted data included study design, treatment groups, control groups, disease model, species, method of cancer induction, intervention method, dosage, route, schedule, and survival outcome, survival data (i.e. disease free survival,

progression free survival), tumour growth rate, intratumoural immune cell fraction (by flow cytometry), macrophage polarisation status (assessed by classical M1/M2 markers), and bibliographical details.

## Statistical analysis

All statistical tests were performed using GraphPad Prism. Mixed-effects analysis (i.e. REML model with data matched within each publication) with Tukey's multiple comparisons test was used for tumour volume, median survival, and stratified CD8 T cell data. Paired T test was used to compare CD8 T cell change between


PI3K $\gamma$  inhibitor and Combo treatment. ns, not significant, \*  $p \leq 0.05$ , \*\*  $p \leq 0.01$ , \*\*\*  $p \leq 0.001$ , \*\*\*\*  $p \leq 0.0001$ .

## Results

### Study characteristics

Following removal of duplicates, a total of 1970 records were identified from searched databases, 36 of which were included in the review. Reasons for removal are summarised in the PRISMA flow diagram (Fig. 1). The earliest publication across all included study was 2016. The tumour models used across these studies were breast (12), colorectal (12),

**Fig. 1** PRISMA flow diagram indicating the number of included studies and reasons for exclusion




lung (6), skin (6), pancreas (3), brain (2), liver (2), prostate (2), head and neck (1), soft tissue (1), gastric (1) and oral (1). Breast and colorectal models were used in 24/36 studies, with CT26 and 4T1 being the most commonly used cell lines. The most frequently used PI3K-gamma inhibitor was IPI-549 (Eganelisib, Infinity Pharmaceuticals). Mouse models were syngeneic in most cases. Tumour induction routes were subcutaneous (28/36), orthotopic (11/36), and genetically engineered (3/36). The most frequently used mouse strains were C57/BL6 (17) and BALB/c (17). 29 (81%) of the studies tested PI3K- $\gamma$  inhibition with an additional agent. The combination therapy was chemotherapy (8), radiotherapy (3), immune checkpoint inhibitors (10), biological agents (3), and a vaccine (1).

### PI3K $\gamma$ inhibitors

A total of 6 different PI3K $\gamma$  inhibitors were used across the studies. The most frequently reported were IPI-549 (21/36) and TG100-115 (9/36). All of the drugs included in the studies reported favourable specificity for the gamma isoform (IC<sub>50</sub> 7.9–83 nM). IPI-549 is the only drug used to have been tested in humans with an acceptable safety profile, including in combination with anti-PD1 [16]. IC<sub>50</sub> values for the other PI3K isoforms were reported where applicable and tended to have higher activity against PI3K delta compared with alpha and beta. Notably, 11 studies reported the use of modifications aimed at enhancing delivery or to combine PI3K $\gamma$  inhibitors with other therapeutics [22, 28–30, 36, 37, 39, 41–43, 48, 49]. This most frequently involved the formation of nanoparticles loaded with additional tumour targeting agents. In some cases, these were conventional chemotherapeutic agents [41]. Other examples include the use of Manganese Oxide based preparations which aim to alleviate tumour hypoxia [22, 28], and photosensitising agents in combination with photodynamic therapy [30]. IPI-549 was used in all reports with a nanoparticle delivery platform. Details of combination therapies including dose, route of administration and schedule are included in Supplementary Table 1.

### Tumour growth

Tumour volume reduced by an average of 37% in animals receiving PI3K $\gamma$  inhibition as a monotherapy, 48% in those receiving single agent comparator therapy, and 69% in those receiving combination treatment (Fig. 2A,B). Responses in the PI3K $\gamma$  monotherapy group were heterogenous with some studies reporting no effect compared to others demonstrating a profound effect on tumour growth. Interestingly, an absence of effect using PI3K $\gamma$  inhibition alone did not correlate with the effects seen with combined therapy. In studies reporting no reduction in tumour growth with PI3K $\gamma$



**Fig. 2** Changes in tumour growth in response to treatment. **A**, Tumour volume normalised to the average untreated tumour volume reported within each study. **B**, Absolute tumour volumes for each treatment group

alone [17, 28, 31, 46] a profound suppression was observed in the combination groups. Some studies reported minimal effect with both PI3K $\gamma$ i and comparator monotherapy but a significant effect with combination treatment (22 Pan02 model, 11).

### Survival

Survival was reported in 25 studies. The median survival (OS, days) was 32.5, 35.5, 36.1 and 57.5 for control, PI3K $\gamma$  inhibition, comparator and combination cohorts, respectively (Supplementary Fig. 3A). Compared to the differences observed in tumour growth kinetics, the effect of combination treatment on survival was more pronounced, with a relative increase in median OS of 15% and 26% in the PI3K $\gamma$  inhibitor and comparator groups compared with 81% in the combination group. In 4 studies median OS was not reached in the combination group [22, 26, 28, 33], which was not observed in any of the other treatment groups across all studies. In these studies, the combination agent was an immune checkpoint inhibitor (anti-PD1/anti-PD-L1). Complete tumour regression (i.e. cure) was observed in 13 tumour models across 9 studies [15, 20, 22, 24–26, 28, 33, 48]. Average rates of regression leading to long term survival were 0%, 1%, 6% and 26% in the untreated, PI3K $\gamma$  inhibitor, comparator and combination groups, respectively (Supplementary Fig. 3B). It was noted that a minority of studies observed animals for recurrence for an extended period of time (> 100 days, Supplementary Fig. 3C).

Additionally, 11/36 studies also reported metastatic burdens based on gross, histological, and radiological findings, and all of which demonstrated reductions in either PI3K $\gamma$ i or combo treated groups [15, 19, 21, 22, 29, 33, 36, 41, 44, 48, 49]. Breast and melanoma models accounted for over half of these reports (6/11) and included direct (i.v injection),



orthotopic (4T1) and spontaneous (MMTV-PyMT) models. Two studies utilised dual tumour models (bilateral flank tumours) to demonstrate an abscopal effect with local treatment to a single tumour [20, 48].

### Changes in immune cell populations

Most studies reported alterations in immune cell populations in tumours using techniques including flow cytometry, immunohistochemistry and RNA sequencing. The majority of studies focused on the myeloid compartment (macrophages, neutrophils and MDSCs) as well as lymphocytes (CD8, CD4). When comparing both PI3K $\gamma$  inhibitor and combination groups to controls, studies reported an increase in the proportion of M1 (inflammatory) macrophages and a decrease in M2 (suppressive) macrophages (Supplementary Fig. 4A,B). Other immune suppressive cells including MDSCs, neutrophils and regulatory T cells were also reduced in PI3K $\gamma$  treated groups. In 27 of the studies reporting on changes in CD8 T cells in the PI3K $\gamma$  inhibitor treated cohort, significant increases were observed in 19 (70%, Supplementary Fig. 4), rising to 91% (20/22) in the combination treatment cohorts. The magnitude of CD8 T cell increase was most substantial in the combination treatment groups (Supplementary Fig. 5A,B). The combination therapies in the 5 studies reporting the most significant increase in T cells were anti-PD1 (3), oncolytic virus, and radiotherapy. There was no correlation between the magnitude of CD8 T cell increase and the effect on tumour growth inhibition (Supplementary Fig. 1). We gathered data on dose scheduling of immune checkpoint inhibitors. In all cases, checkpoint inhibitors were initiated concurrently with PI3K $\gamma$  inhibitors, with the total number of doses ranging between three and seven (Supplementary Table 2). In addition to quantitation of T lymphocytes, a number of studies interrogated their activation status with a focus on CD8+ T cells. In the majority of cases, this involved protein quantification (flow cytometry, ELISA) of cytotoxic markers including granzyme B, perforin, interferon- $\gamma$ , CD107a and TNF-alpha. Two studies used interferon- $\gamma$  ELISPOT assays to demonstrate antigen specificity of CD8+ T cells [19, 40].

Eight (8/36) of the studies described a non-immunological target for PI3K $\gamma$  inhibition [17, 19, 24, 27, 34, 37, 47, 50]. This included direct targeting of tumour cells, increasing tumour cell sensitivity to chemotherapy, stem cells and stromal/extracellular matrix remodelling. One of these used an immune suppressed PDX model [34], the remaining were syngeneic. There was no significant difference in average changes in survival when immune versus non-immune studies were compared (Table 1).

### Discussion

This systematic review of the preclinical literature summarises the current evidence supporting the use of PI3K $\gamma$  inhibitors for the treatment of solid tumours. Without specifying the inclusion of studies focusing on immune modulation a priori, we found that a minority (8/36) used PI3K $\gamma$  inhibitors with the aim of targeting tumour cells or other non-immune components. When tumour growth and survival data were meta-analysed, PI3K $\gamma$  when combined with any additional treatment had a more pronounced effect than monotherapies. This was particularly the case for combined treatment with immune checkpoint inhibitors. These effects were seen across tumour models and using different PI3K $\gamma$  inhibitors. Taken together, these consistent results demonstrate that PI3K $\gamma$  represents a promising target for clinical translation.

Combination treatment strategies have gained traction in light of the heterogeneous response to novel immunotherapeutics observed in clinical studies. Preclinical work has highlighted the contribution of macrophages to intratumoural immune suppression, limiting the effect of drugs relying on cytolytic T cell activity [52–55]. Macrophage pleiotropy and the role that functional subsets may play in promoting anti-tumour immunity has shifted the focus away from depletion and towards reprogramming. This approach takes advantage of the anti-tumour TAM functions that may be essential in permitting immune mediated tumour killing.

The predominant PI3K $\gamma$  inhibitors described in included studies, notably IPI-549 and TG100-115, are reported to have favourable specificity for the gamma isoform [56, 57]. This, combined with the myeloid specificity of PI3K $\gamma$ , translates into a highly targeted therapy with minimal off target effects. The inclusion of various solid tumour models in reported studies, including breast, colorectal, lung, skin, pancreas, brain, liver, prostate, head and neck, soft tissue, gastric, and oral cancers, underscores the broad applicability of PI3K $\gamma$ -targeted strategies. This is in keeping with clinical data that suggest a pro-tumoural role for macrophages in most tumour settings [58–62].

Combination therapies emerged as a recurrent theme, featured in 81% of the studies. These combinations spanned chemotherapy, radiotherapy, immune checkpoint inhibitors, biological agents, and vaccines, reflecting a multifaceted approach to counter myeloid-driven immune suppression. We did not identify a single group of tumour models where PI3K $\gamma$  inhibition had a more pronounced effect compared with combination therapies. Notably, the heterogeneous response to PI3K $\gamma$  monotherapy in tumour growth kinetics suggested the need for nuanced considerations in selecting optimal treatment regimens. However, the pronounced reduction observed in tumour growth with combination therapies highlights the potential synergistic effects when

**Table 1** Summary of the study characteristics of included publications

	Reference	Inhibitor	Cancer type	Cell line	Model	Mouse strain	Combo type
1	De Vera et al. [17]	IPI-549	Colon	SW620	SC	athymic NCR	Paclitaxel
2	Zha et al. [18]	IPI-549	Colon	CT26	SC	Balb/c	CT-26 C3 KO
3	Chung et al. [19]	AS-605240	Prostate	PKC	GEM	PB-Cre4; p53; Kras	
4	Yoon et al. [20]	BR101801	Colon	CT26	SC	Balb/c	IR
5	Qin et al. [21]	TG100-115	Breast	4T1	SC	Balb/c	PLG-CA4
6	Yu et al. [22]	IPI-549	Breast	4T1	SC	Balb/c	MnO2 nanoparticle
7	Foubert et al. [23]	TG100-115	Lung	LLC	SC	C57Bl/6 J	
8	Li et al. [24]	IPI-549	Breast	4T1	SC	Balb/c	doxorubicin
9	Li et al. [25]	TG100-115	Brain	CT-2A GL261	ortho ortho	C57BL/6 C57BL/6	temozolomide
10	Han et al. [26]	duvelisib (IPI-145)	Breast	4T1-luc/PDX	SC	Balb/c/Huaman-ised	RT/PD-1
11	Martin et al. [27]	AS-605240	Kaposi's Sarcoma	SV40	SC	athymic mice	rapamycin
12	Guan et al. [28]	IPI-549	Colon	CT26 luc+	SC	Balb/c	RT
13	Wang et al. [29]	IPI-549	Skin	B16F10	SC	C57BL/6	CpG (1 mg/kg) in MOF Nanoparticle
14	Ding et al. [30]	IPI-549	Colon	CT26	SC	Balb/c	photosensitizer
15	Liu et al. [31]	IPI-549	Skin	B16F10	SC	C57BL/6	OVM
			Colon	MC38	SC	C57BL/6	OVM
			Pancreas	Pan02	SC	C57BL/6	OVM
			Prostate	RM-1	SC	C57BL/6	OVM
			Breast	4T1	SC	Balb/c	OVM
16	Du et al. [32]	IPI-549	Colon	MC38	SC	C57BL/6 J	Neoantigen vaccine
17	De Henau et al. [33]	IPI-549	Skin	B16-GMCSF	ID	C57BL/6 J	anti-PD-1/CTLA-4
			Breast	4T1	SC	Balb/c	anti-PD-1/CTLA-4
18	Chang et al. [34]	AS-605240	Breast	MDA-MB-231	ortho	SCID	Paclitaxel (10 mg/kg)
19	Liu et al. [35]	TG100-115	Liver	Hepa1-6	ortho,	C57BL/6 J	anti-PD-1
20	Shen et al. [36]	IPI-549	Colon	CT26	SC	Balb/c	Oxaliplatin
21	Jiang et al. [37]	IPI-549	Breast	4T1	Ortho	Balb/c	silibinin (5 mg/kg, IV)
22	Schmid et al. [38]	TG100-115	Lung	LLC	SC	C57BL/6	
		AS-605240	Lung	LLC	SC	C57BL/6	
23	Li and Zhao [39]	TG100-115	Liver	Hep-3B	SC	nude	sorafenib (20 mg/kg)
24	Davis et al. [40]	IPI-145	Oral	MOC1	SC	C57BL/6	anti-PD-L1
25	Song et al. [41]	IPI-549	Breast	MMTV-PyMT/4T1	GEM/Ortho	MMTV-PyMT/ Balb/c	anti-PD-1, Paclitaxel
26	Zhang et al. [42]	IPI-549	Pancreas	KPC	Ortho	C57BL/6	
			Skin	BPD6	SC	C57BL/6	
27	Miyazaki et al. [43]	IPI-549	Brain	TMZ-resistant TS	SC	C57BL/6	anti-PD-L1
28	Kaneda et al. [44]	TG100-115	Pancreas	KPC	Ortho/GEM	C57BL6/FVB	Gemcitabine, anti-PD-1
29	Luo et al. [45]	IPI-549	Gastric	MFC	ID	615	
30	Carnevalli et al. [46]	AZD3458	Colon	MC38	SC	C57/Bl6	anti-CTLA-4/ PD-L1/PD-1
			Colon	CT26	SC	Balb/c	anti-PD-L1

**Table 1** (continued)

	Reference	Inhibitor	Cancer type	Cell line	Model	Mouse strain	Combo type
31	Xu et al. [47]	IPI-549	Breast Lung	4T1 Stem cells	Ortho SC	Balb/c Nude athymic BALB/c	anti-PD-1 EGFR inhibitor
32	Li et al. 2022 [48]	IPI-549	Colon	CT26 fLuc+	ID,	Balb/c	anti-PD-L1
33	Han et al. 2022 [49]	IPI-549	Breast Skin	4T1 B16/F10	SC Forced Met, SC tumor,	Balb/c C57/BL6J	anti-PD-L1 GFE1 peptide tar- geting exosome
34	Lee et al. [50]	TG100-115	Colon	CT26	SC	Balb/c	
35	Kaneda et al. [15]	IPI-549 TG115-110	Head and Neck	HPV + HNSCC	SC	C57Bl/6 J	
			Lung	LLC	SC	C57Bl/6 J	
			Breast	PyMT	Ortho	C57Bl/6 J	
			Skin	HPV- / HPV +	SC	C3He/J	Anti-PD1
36	Joshi et al. 2020 [51]	IPI-549	Lung	LLC	SC	C57/BL6	

PI3K $\gamma$  inhibition is integrated into broader treatment strategies. It was clear that most studies rationalised the use PI3K $\gamma$  inhibitors due to their capacity to reverse myeloid driven immune suppression. This is likely to be the reason that the most frequently used combination treatment was immune checkpoint inhibitor therapy. The reduced tumour growth rate observed with combination treatment translated into improved survival in some studies. The relative increase in median overall survival was notably higher in the combination group compared to both PI3K $\gamma$  monotherapy and comparator groups. This trend suggests that the synergistic effects observed in tumour growth kinetics translate into significant improvements in survival outcomes. This was further emphasised by the finding that only groups receiving combination treatment achieved tumour regression and ‘cure’ across all studies.

The immunological landscape within the TME underwent notable transformations upon PI3K $\gamma$  inhibition. Studies focused on alterations in myeloid cell populations encompassing macrophages, MDSCs, dendritic cells and neutrophils, as well as regulatory T cells. Alterations in NK cell populations were rarely reported. The majority of studies reported both quantitative and functional changes in these populations using techniques including flow cytometry, RNA sequencing, immunohistochemistry, and suppression assays. For myeloid characterisation, changes in the absolute number of macrophages were variable, but more consistent were the reported increases in M1 macrophages and decreases in M2 macrophages. This was commonly based on the expression of CD80 and iNOS for M1, and CD206 and arginase for M2. Gene expression studies, particularly RNA sequencing, provided additional clarity on the potential reprogramming in response to PI3K $\gamma$  inhibition. Gene set enrichment analyses highlighted changes to inflammatory

and suppressive pathways as expected, but also additional pathways including antigen presentation, metabolism and phagocytosis [18, 26, 33, 35, 46]. In addition to macrophages, a number of studies specifically investigated the effect of treatment on MDSCs [22, 23, 26, 28, 30, 31]. Similar to the effects observed in macrophages, PI3K $\gamma$  inhibition reduced phosphorylation of AKT, a recognised downstream signal of PI3K activation. This corresponded with reduced expression of immune suppression markers and also T cell suppression. Amongst the studies that reported a decrease in the total number of MDSCs, one demonstrated increased MDSC apoptosis in response to PI3K $\gamma$  inhibition [30]. Finally, some studies highlighted the effect of treatment on regulatory T cell populations [20, 26, 30, 40, 41]. This was particularly the case in studies using inhibitors with activity against PI3K $\delta$ . In these studies, changes in regulatory T cell populations were accompanied by the previously discussed changes in myeloid cells. In the absence of regulatory T cell depletion models, it is however difficult to determine the relative contribution of these suppressive immune cell populations within the TME.

Importantly, our analysis revealed a substantial increase in CD8 T cell populations, particularly in the combination treatment cohorts. These T cells were frequently reported as having high expression of effector markers including interferon- $\gamma$ , TNA- $\alpha$ , granzyme B, and perforin. We observed no correlation between the magnitude of CD8 T cell increase and the changes in tumour volume, suggesting that the quality of T cells (i.e. antigen specific, activated) is critical for anti-tumour activity. To discern the mechanism behind increased T cell numbers, some studies highlighted the reduced proliferative suppression capacity of PI3K $\gamma$  inhibitor treated macrophages [23, 33, 63]. These findings further support the rationale for combining PI3K $\gamma$  inhibitors



with treatments that depend on adaptive anti-tumour immunity for therapeutic effect.

While most studies focused on immunological targets, a subset explored non-immunological aspects of PI3K $\gamma$  inhibition, such as direct targeting of tumour cells, increasing chemosensitivity, and alterations in the tumour microenvironment. De Vera et al. demonstrated that IPI-549 sensitised multi-drug resistant (P-gp overexpressing) cell lines to taxane based chemotherapy by inhibiting P-gp mediated drug efflux [17]. The efficacy of combination therapy was more pronounced in P-gp overexpressed tumour. Chung et al. showed that PI3K $\gamma$  was expressed in a genetically engineered mouse model (GEMM) of prostate cancer (Trp53/KRAS<sup>G</sup> [12]<sup>D</sup>) where epithelial-to-mesenchymal transition was observed [19]. Only 10% of tumour cells in this model expressed PI3K $\gamma$  and whilst inhibition *in vitro* has a profound effect, this did not translate in the *in vivo* setting. In another study, the authors reported the protective role for PI3K $\gamma$  inhibition in doxorubicin induced cardiotoxicity by augmenting cardiocyte autophagy [24]. Treatment also led to a reversal of tumour immune suppression. In a rare subtype of breast cancer, one group reported a direct effect on tumour cells [34], and also indirectly by reducing TAM tumour cell EMT [50]. These studies highlighted that PI3K $\gamma$  inhibition may have alternative functions outside of the immunological context in distinct tumour types.

Several studies utilised drug modifications, including nanoparticle delivery platforms, highlighting the innovation in drug delivery strategies to enhance the therapeutic efficacy of PI3K $\gamma$  inhibitors. The incorporation of these advanced delivery methods may address challenges related to drug bioavailability and distribution within the TME. They also permit dual targeting with additional agents that may ameliorate other barriers to anti-tumour immunity.

The robust preclinical evidence has driven the development of several clinical PI3K $\gamma$  inhibitors, with IPI-549 (Infinity Pharmaceuticals) being the most advanced to date. The results of a phase I/IIb trial combining IPI-549 with anti-PD1 were favourable and pave the way for phase 2 studies [16]. The most significant translational challenge is likely to be the selection of candidate combination therapies as well as appropriate tumour settings.

In conclusion, the results of this systematic review underscore the potential of PI3K $\gamma$  inhibition as a promising approach to reverse myeloid-driven immune suppression in the TME. The synergistic effects observed in combination therapies, coupled with the modulation of immune cell populations, provide a compelling rationale for further clinical exploration. As the field advances, understanding the intricate interplay between PI3K $\gamma$  inhibition, immune modulation, and tumour-specific factors will be crucial for optimising therapeutic strategies tailored to diverse solid tumour types. Future clinical trials driven

by the findings of these preclinical studies hold the potential to unlock new dimensions in cancer immunotherapy.

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1007/s00262-024-03779-2>.

**Author contributions** K.S performed the literature search and reviewed the final manuscript. K.J, H.X, S.N.R wrote the manuscript. K.J and E.O.N designed the concept of the study. K.J, E.O.N, K.S, H.X and S.N.R reviewed the final version of the manuscript. K.J and H.X screened abstracts and extracted data. K.J and H.X performed the data analysis.

## Declarations

**Conflict of interest** The authors declare no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

1. Nakamura K, Smyth MJ (2020) Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. *Cell Mol Immunol* 17(1):1–12. <https://doi.org/10.1038/s41423-019-0306-1>
2. DeNardo DG, Ruffell B (2019) Macrophages as regulators of tumour immunity and immunotherapy. *Nat Rev Immunol* 19(6):369–382. <https://doi.org/10.1038/s41577-019-0127-6>
3. Caras I et al (2011) Influence of tumor cell culture supernatants on macrophage functional polarization: *in vitro* models of macrophage-tumor environment interaction. *Tumori* 97:647–654
4. Hagemann T et al (2006) Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. *J Immunol* 176:5023–5032
5. Murray PJ et al (2014) Macrophage activation and polarization: nomenclature and experimental guidelines. *Immunity* 41:14–20
6. Ma R et al (2016) Tumor cell-derived microparticles polarize M2 tumor-associated macrophages for tumor progression. *Oncoimmunology* 5(4):e1118599
7. Cirri P, Chiarugi P (2012) Cancer-associated-fibroblasts and tumour cells: A diabolic liaison driving cancer progression. *Cancer Metastasis Rev* 31:195–208
8. Sun Q et al (2023) Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. *Signal Transduct Target Ther* 8:320
9. Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK (2012) Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. *Semin Cancer Biol* 22:275–281
10. Willingham SB et al (2012) The CD47-signal regulatory protein alpha (SIRP $\alpha$ ) interaction is a therapeutic target for human solid tumors. *Proc Natl Acad Sci USA* 109:6662–6667

11. Joshi S, Singh AR, Zulcic M, Durden DL (2014) A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1 $\alpha$  and HIF2 $\alpha$  stability and tumor growth, angiogenesis, and metastasis. *Mol Cancer Res* 12(10):1520–1531
12. Serini S, Ottens Vasconcelos R, Fasano E, Calviello G (2016) Epigenetic regulation of gene expression and M2 macrophage polarization as new potential omega-3 polyunsaturated fatty acid targets in colon inflammation and cancer. *Expert Opin Therap Targets* 20(7):843–858
13. Niu Y, Chen J, Qiao Y (2022) Epigenetic modifications in tumor-associated macrophages: a new perspective for an old foe. *Front Immunol* 13:836223
14. Lanahan SM, Wymann MP, Lucas CL (2022) The role of PI3K $\gamma$  in the immune system: new insights and translational implications. *Nat Rev Immunol* 22(11):687–700. <https://doi.org/10.1038/s41577-022-00701-8>
15. Kaneda MM et al (2016) PI3K $\gamma$  is a molecular switch that controls immune suppression. *Nature* 539:437–442
16. Hong DS et al (2023) Eganalisib, a first-in-class PI3K $\gamma$  inhibitor, in patients with advanced solid tumors: results of the phase 1/1b MARIO-1 trial. *Clin Cancer Res* 29(12):2210–2219. <https://doi.org/10.1158/1078-0432.CCR-22-3313>
17. De Vera AA et al (2019) Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: in vitro and in vivo. *Cancer Lett* 442:91–103
18. Zha H et al (2019) Intracellular activation of complement C3 leads to PD-L1 antibody treatment resistance by modulating tumor-associated macrophages. *Cancer Immunol Res* 7:193–207
19. Chung WC, Zhou X, Atfi A, Xu K (2020) PIK3CG is a potential therapeutic target in androgen receptor-indifferent metastatic prostate cancer. *Am J Pathol* 190:2194–2202
20. Yoon YN et al (2022) PI3K $\delta/\gamma$  inhibitor BR101801 extrinsically potentiates effector CD8+ T cell-dependent antitumor immunity and abscopal effect after local irradiation. *J Immunother Cancer* 10:e003762
21. Qin H et al (2019) PI3K $\gamma$  inhibitor attenuates immunosuppressive effect of poly(l-glutamic acid)-combretastatin A4 conjugate in metastatic breast cancer. *Adv Sci* 6:1900327
22. Yu M et al (2019) Multifunctional nanoregulator reshapes immune microenvironment and enhances immune memory for tumor immunotherapy. *Adv Sci* 6:1900037
23. Foubert P, Kaneda MM, Varner JA (2017) PI3K $\gamma$  activates integrin  $\alpha 4$  and promotes immune suppressive myeloid cell polarization during tumor progression. *Cancer Immunol Res* 5:957–968
24. Li M et al (2018) Phosphoinositide 3-kinase gamma inhibition protects from anthracycline cardiotoxicity and reduces tumor growth. *Circulation* 138:696–711
25. Li J et al (2021) PI3K $\gamma$  inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response. *Proc Natl Acad Sci U S A* 118:e2009290118
26. Han MG, Jang BS, Kang MH, Na D, Kim IA (2021) PI3K $\gamma$  $\delta$  inhibitor plus radiation enhances the antitumor immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model. *Eur J Cancer* 157:450–463
27. Martin D et al (2011) PI3K $\gamma$  mediates Kaposi's sarcoma-associated herpesvirus vGPCR-induced sarcomagenesis. *Cancer Cell* 19:805–813
28. Guan X et al (2022) Nanoparticle-enhanced radiotherapy synergizes with PD-L1 blockade to limit post-surgical cancer recurrence and metastasis. *Nat Commun* 13:1–17
29. Wang S et al (2022) Non-cytotoxic nanoparticles re-educating macrophages achieving both innate and adaptive immune responses for tumor therapy-NC-ND license. *Asian J Pharm Sci* 17:557–570
30. Ding D et al (2021) Multifunctional nanodrug mediates synergistic photodynamic therapy and MDSCs-targeting immunotherapy of colon cancer. *Adv Sci* 8:2100712
31. Liu Y et al (2022) Overcoming resistance to oncolytic virus M1 by targeting PI3K- $\gamma$  in tumor-associated myeloid cells. *Mol Ther* 30(12):3677–3693. <https://doi.org/10.1016/j.ymthe.2022.05.008>
32. Du Y et al (2022) Peptidic microarchitecture-trapped tumor vaccine combined with immune checkpoint inhibitor or PI3K $\gamma$  inhibitor can enhance immunogenicity and eradicate tumors. *J Immunother Cancer* 10:e003564
33. De Henau O et al (2016) Overcoming resistance to checkpoint blockade therapy by targeting PI3K $\gamma$  in myeloid cells. *Nature* 539:443–447
34. Chang J et al (2020) Targeting PIK3CG in combination with paclitaxel as a potential therapeutic regimen in claudin-low breast cancer. *Cancer Manag Res*. <https://doi.org/10.2147/CMAR.S250171>
35. Liu X et al (2022) Targeting PI3K $\gamma$ /AKT pathway remodels LC3-associated phagocytosis induced immunosuppression after radiofrequency ablation. *Adv Sci* 9:2102182
36. Shen Y et al (2021) Tailoring chemoimmunostimulant bioscaffolds for inhibiting tumor growth and metastasis after incomplete microwave ablation. *ACS Nano* 15:20414–20429
37. Jiang M et al (2020) Tumor-targeted delivery of silibinin and IPI-549 synergistically inhibit breast cancer by remodeling the microenvironment. *Int J Pharm* 581:119239
38. Schmid MC et al (2011) Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3K $\gamma$ , a single convergent point promoting tumor inflammation and progression. *Cancer Cell* 19:715–727
39. Li G, Zhao L (2019) Sorafenib-loaded hydroxyethyl starch-TG100-115 micelles for the treatment of liver cancer based on synergistic treatment. *Drug Deliv* 26:756–764
40. Davis RJ et al (2017) Anti-PD-L1 efficacy can be enhanced by inhibition of myeloid-derived suppressor cells with a selective inhibitor of PI3K $\delta/\gamma$ . *Cancer Res* 77:2607–2619
41. Song Y et al (2022) Albumin nanoparticle containing a PI3K $\gamma$  inhibitor and paclitaxel in combination with  $\alpha$ -PD1 induces tumor remission of breast cancer in mice. *Sci Transl Med* 14:3649
42. Zhang X, Shen L, Liu Q, Hou L, Huang L (2019) Inhibiting PI3 kinase- $\gamma$  in both myeloid and plasma cells remodels the suppressive tumor microenvironment in desmoplastic tumors. *J Control Release* 309:173–180
43. Miyazaki T et al (2020) Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3K $\gamma$  inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells. *Brain Tumor Pathol* 37:41–49
44. Kaneda MM et al (2016) Macrophage PI3K $\gamma$  drives pancreatic ductal adenocarcinoma progression. *Cancer Discov* 8:870–885
45. Luo Q et al (2020) Lipid accumulation in macrophages confers protumorigenic polarization and immunity in gastric cancer. *Cancer Sci* 111:4000–4011
46. Carnevalli LS et al (2021) Macrophage activation status rather than repolarization is associated with enhanced checkpoint activity in combination with PI3K $\gamma$  Inhibition. *Mol Cancer Therap* 20(6):1080–1091. <https://doi.org/10.1158/1535-7163.MCT-20-0961>
47. Xu Y et al (2022) The efficacy of PI3K $\gamma$  and EGFR inhibitors on the suppression of the characteristics of cancer stem cells. *Sci Rep* 12:1–11
48. Li S et al (2022) Engineering ROS-responsive bioscaffolds for disrupting myeloid cell-driven immunosuppressive niche to enhance PD-L1 blockade-based postablative immunotherapy. *Adv Sci* 9:2104619

49. Han X et al (2022) Genetically engineered exosomes for targetedly preventing premetastatic niche formation and suppressing postoperative melanoma lung metastasis. *Nano Today* 46:101597
50. Lee YS et al (2020) The FBW7-MCL-1 axis is key in M1 and M2 macrophage-related colon cancer cell progression: validating the immunotherapeutic value of targeting PI3K $\gamma$ . *Exp Mol Med* 52:815–831
51. Joshi S, Singh AR, Zulcic M, Durden DL (2014) A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1 $\alpha$  and HIF2 $\alpha$  stability and tumor growth, angiogenesis, and metastasis. *Mol Cancer Res* 12:1520–1531
52. DeNardo DG, Ruffell B (2019) Macrophages as regulators of tumour immunity and immunotherapy. *Nat Rev Immunol* 19:369–382
53. Chen S et al (2023) Macrophages in immunoregulation and therapeutics. *Signal Transd Target Ther* 8(1):207. <https://doi.org/10.1038/s41392-023-01452-1>
54. Jones KI et al (2018) Radiation combined with macrophage depletion promotes adaptive immunity and potentiates checkpoint blockade. *EMBO Mol Med* 10:e9342
55. Seifert L et al (2016) Radiation therapy induces macrophages to suppress T-cell responses against pancreatic tumors in mice. *Gastroenterology* 150:1659–1672.e5
56. Evans CA et al (2016) Discovery of a selective phosphoinositide-3-kinase (PI3K)- $\gamma$  inhibitor (IPI-549) as an immuno-oncology clinical candidate. *ACS Med Chem Lett* 7(9):862–867. <https://doi.org/10.1021/acsmchemlett.6b00238>
57. Doukas J et al (2007) Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction. *Biochem Soc Trans* 35(2):204–206
58. Pittet MJ, Michielin O, Migliorini D (2022) Clinical relevance of tumour-associated macrophages. *Nat Rev Clin Oncol* 19(6):402–421. <https://doi.org/10.1038/s41571-022-00620-6>
59. Yahaya MAF et al (2019) Tumour-associated macrophages (TAMs) in colon cancer and how to reeducate them. *J Immunol Res* 2019(1):2368249. <https://doi.org/10.1155/2019/2368249>
60. Jeong H, Hwang I, Kang SH, Shin HC, Kwon SY (2019) Tumor-associated macrophages as potential prognostic biomarkers of invasive breast cancer. *J Breast Cancer* 22:38
61. Yi B et al (2023) Prognostic significance of tumor-associated macrophages polarization markers in lung cancer: a pooled analysis of 5105 patients. *Biosci Rep*. <https://doi.org/10.1042/BSR20221659>
62. Yu M et al (2019) Prognostic value of tumor-associated macrophages in pancreatic cancer: a meta-analysis. *Cancer Manag Res*. <https://doi.org/10.2147/CMAR.S196951>
63. Holmgaard RB, Zamarin D, Lesokhin A, Merghoub T, Wolchok JD (2016) Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. *EBioMedicine* 6:50–58

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.